Frost & Sullivan Publishes Initiation Coverage Report On Cellect Biotechnology - Equity Research Is Published In The framework Of The Tel Aviv Stock Exchange Analysis Program

Cellect Biotechnology Ltd, based in Israel, has developed an innovative technology which enables the production of stem cells to therapies and treatments that require stem cells as the main ‘raw material’. The company trades on both the Tel Aviv Stock Exchange (TASE) and NASDAQ, and had a market capitalisation at TASE of ca. 45 million USD (prior to the release of Frost & Sullivan report today).